ENB Therapeutics Announces Orphan Drug Designation Granted by FDA for ENB-003 for the Treatment of Pancreatic Cancer

ENB-003 is a first in class small molecule therapeutic selectively targeting the ETB receptor – a novel immune checkpoint

See more here